Nam-Hyuk Cho1,2,3†, Taek-Chin Cheong1,2,4†, Ji HyunMin5,6†, Jun HuaWu6†, Sang Jin Lee4, Daehong Kim4, Jae-Seong Yang7, Sanguk Kim7, Young Keun Kim5,6* and Seung-Yong Seong1,2,6*
1Department of Microbiology and Immunology, 2Department of Biomedical Sciences, Seoul National University College of Medicine and Institute of Endemic Diseases, Seoul National University Medical Research Center and 3Bundang Hospital, Seoul, Republic of Korea, 4Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea, 5Department of Materials Science and Engineering, Korea University, Seoul, Republic of Korea, 6Pioneer Research Center for Biomedical Nanocrystals, Korea University, Seoul, Republic of Korea, 7Department of Life Science and School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, Pohang, Gyungbuk, Republic of Korea; †These authors contributed equally to this work.
Dendritic cell-based cancer immunotherapy requires tumour antigens to be delivered efficiently into dendritic cells and their migration to be monitored in vivo. Nanoparticles have been explored as carriers for antigen delivery, but applications have been limited by the toxicity of the solvents used to make nanoparticles, and by the need to use transfection agents to deliver nanoparticles into cells. Here we show that an iron oxide-zinc oxide core-shell nanoparticle can deliver carcinoembryonic antigen into dendritic cells while simultaneously acting as an imaging agent. The nanoparticle-antigen complex is efficiently taken up by dendritic cells within one hour and can be detected in vitro by confocal microscopy and in vivo by magnetic resonance imaging. Mice immunized with dendritic cells containing the nanoparticle-antigen complex showed enhanced tumour antigen specific T-cell responses, delayed tumour growth and better survival than controls.